“I advise strongly against trying to pursue ketamine, commercially or clinically, because of safety concerns and the risk of losing our opportunity to study it

“I advise strongly against trying to pursue ketamine, commercially or clinically, because of safety concerns and the risk of losing our opportunity to study it rigorously,” said Kolevzon [the clinical director] Research to gain quality evidence is good, but sometimes other considerations outweigh that. Visible improvement in the sufferers of a rare disease may be such a case.